ProCE Banner Activity

SOPHIA: Second Interim OS Analysis of Margetuximab + CT vs Trastuzumab + CT for HER2+ MBC After Previous HER2 Therapy

Slideset Download
Conference Coverage
In patients with HER2+ metatstatic breast cancer after prior anti-HER2 therapy, margetuximab + chemotherapy continues to provide PFS benefit vs trastuzumab + chemotherapy with similar OS benefit in the second interim survival analysis of SOPHIA.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen